Single drug to treat all tumors!!!

Welcome Dear Guest

To create a new topic please register on the forums. For help contact : discussdentistry@hotmail.com

This topic has 2 replies, 1 voice, and was last updated 29/04/2013 at 6:03 pm by drsnehamaheshwari.

Currently, there are 0 users and 2 guests visiting this topic.

Viewing 3 posts - 1 through 3 (of 3 total)

Author

Posts
03/04/2013 at 3:29 pm #11419

drsnehamaheshwari
Offline
Registered On: 16/03/2013
Topics: 110
Replies: 239
Has thanked: 0 times
Been thanked: 0 times

Researchers might have found the Holy Grail in the war against cancer, a miracle drug that has killed every kind of cancer tumor it has come in contact with as reported. A single drug can shrink or cure human breast, ovary, colon, bladder, brain, liver, and prostate tumors that have been transplanted into mice, researchers have found. The treatment, an antibody that blocks a “do not eat” signal normally displayed on tumor cells, coaxes the immune system to destroy the cancer cells.

A decade ago, biologist Irving Weissman of the Stanford University School of Medicine in Palo Alto, California, discovered that leukemia cells produce higher levels of a protein called CD47 than do healthy cells. CD47, he and other scientists found, is also displayed on healthy blood cells; it’s a marker that blocks the immune system from destroying them as they circulate. Cancers take advantage of this flag to trick the immune system into ignoring them. In the past few years, Weissman’s lab showed that blocking CD47 with an antibody cured some cases of lymphomas and leukemias in mice by stimulating the immune system to recognize the cancer cells as invaders. Now, he and colleagues have shown that the CD47-blocking antibody may have a far wider impact than just blood cancers.

“What we’ve shown is that CD47 isn’t just important on leukemias and lymphomas,” says Weissman. “It’s on every single human primary tumor that we tested.” Moreover, Weissman’s lab found that cancer cells always had higher levels of CD47 than did healthy cells. How much CD47 a tumor made could predict the survival odds of a patient.

To determine whether blocking CD47 was beneficial, the scientists exposed tumor cells to macrophages, a type of immune cell, and anti-CD47 molecules in petri dishes. Without the drug, the macrophages ignored the cancerous cells. But when the anti-CD47 was present, the macrophages engulfed and destroyed cancer cells from all tumor types.

Next, the team transplanted human tumors into the feet of mice, where tumors can be easily monitored. When they treated the rodents with anti-CD47, the tumors shrank and did not spread to the rest of the body. In mice given human bladder cancer tumors, for example, 10 of 10 untreated mice had cancer that spread to their lymph nodes. Only one of 10 mice treated with anti-CD47 had a lymph node with signs of cancer. Moreover, the implanted tumor often got smaller after treatment—colon cancers transplanted into the mice shrank to less than one-third of their original size, on average. And in five mice with breast cancer tumors, anti-CD47 eliminated all signs of the cancer cells, and the animals remained cancer-free 4 months after the treatment stopped.

“We showed that even after the tumor has taken hold, the antibody can either cure the tumor or slow its growth and prevent metastasis,” says Weissman.

Although macrophages also attacked blood cells expressing CD47 when mice were given the antibody, the researchers found that the decrease in blood cells was short-lived; the animals turned up production of new blood cells to replace those they lost from the treatment, the team reports online today in the Proceedings of the National Academy of Sciences.

Cancer researcher Tyler Jacks of the Massachusetts Institute of Technology in Cambridge says that although the new study is promising, more research is needed to see whether the results hold true in humans. “The microenvironment of a real tumor is quite a bit more complicated than the microenvironment of a transplanted tumor,” he notes, “and it’s possible that a real tumor has additional immune suppressing effects.”

Another important question, Jacks says, is how CD47 antibodies would complement existing treatments. “In what ways might they work together and in what ways might they be antagonistic?” Using anti-CD47 in addition to chemotherapy, for example, could be counterproductive if the stress from chemotherapy causes normal cells to produce more CD47 than usual.

Weissman’s team has received a $20 million grant from the California Institute for Regenerative Medicine to move the findings from mouse studies to human safety tests. “We have enough data already,” says Weissman, “that I can say I’m confident that this will move to phase I human trials.”



28/04/2013 at 4:01 pm #16545

drsnehamaheshwari
Offline
Registered On: 16/03/2013
Topics: 110
Replies: 239
Has thanked: 0 times
Been thanked: 0 times

With some new, potentially lifesaving cancer drugs costing up to $138,000 a year, about 120 leading cancer specialists have joined forces in an unusual protest aimed at getting pharmaceutical companies to cut prices.

Charging high prices for drugs cancer patients need to survive is like “profiteering” from a natural disaster by jacking up prices for food and other necessities, leading cancer doctors and researchers from around the world contend in a new paper published in Blood, the journal of the American Society of Hematology.

Of 12 new cancer drugs that received FDA approval last year, 11 of them cost in excess of $100,000 a year—prices that the specialists attack as “astronomical,” “unsustainable,” and maybe even immoral. What’s more, only three of these drugs were found to improve patient survival rates and of these, two only increased it by less than two months, according to the Washington Post.

“Advocating for lower drug prices is a necessity to save the lives of patients,” say the specialists who wrote the paper, who specialize in chronic myelogenous leukemia (CML), but emphasize that sky-high drug costs affect patients with many types of cancer.

Going Bankrupt to Stay Alive

“Medical illness and drug prices are the single most frequent cause of personal bankruptcy” in the US, according to the specialists, where patients’ copayments on drug prices average 20 percent of the total cost of the drug. That means that cancer patients often face having to shell out $20,000 to $30,000 a year, simply to stay alive.

The specialists also note that astronomical drug prices may be the single most common reason why patients stop taking lifesaving drugs. This is particularly true for those with CML, which requires daily treatment for long-term survival.

As a result the paper says, “grateful patients may have become the ‘financial victims’ of the treatment success, having to pay the high price annually to stay alive.” One study found that 10 percent of cancer patients fail to fill new prescriptions for oral cancer drugs.

For some patients, such as breast cancer survivor Patti Tyree, medical costs not the disease are stealing their future. The 57-year-old postal worker inherited $25,000, but after just one round of treatment for breast cancer, nearly half of the money is gone and bills continue to pour in, she told USA Today.

One of the more expensive therapies for CML is Gleevac, a cancer drug that generated $4.7 billion in sales last year, making it the bestselling drug for its manufacturer, Novartis. Another Novartis leukemia drug, Tasigna, had sales of $1 billion, according to The New York Times.

Doctors Pressure Drug Companies to Slash Prices

Some of the specialists who joined the protest were inspired by the doctors from Memorial Sloan Kettering Cancer Center (MSKCC) who refused to use a new colon cancer drug called Zaltrap because it cost more than twice as much ($11,063 on average for one month of treatment) as another drug (Avastin) without improving outcomes.

“Soaring spending has presented the medical community with a new obligation. When choosing treatments for a patient, we have to consider the financial strains they may cause alongside the benefits they might deliver,” the MSKCC doctors wrote in an October, 2012 op-ed for The New York Times about their boycott.

Subsequently, the drug’s manufacturer slashed the price by 50 percent.



29/04/2013 at 6:03 pm #16548

drsnehamaheshwari
Offline
Registered On: 16/03/2013
Topics: 110
Replies: 239
Has thanked: 0 times
Been thanked: 0 times

Cancer Drugs Rank Among the World’s Most Expensive

The idea that "one cannot put a price on a human life” has led to wildly overblown healthcare costs in the U.S., estimated at $2.7 trillion in 2011, according to the paper’s authors, who urge insurers and government to more aggressively negotiate with pharmaceutical companies.

Many reports show that cancer drugs consistently rank as the most expensive therapies, even though some only extend life by a few months or offer no benefit over older, less expensive drugs.

The paper discussed Gleevac, which was originally priced at about $30,000 a year when it was approved in 2001. Since then, the price has tripled. However, its manufacturer told The New York Times that relatively few patients actually pay the full cost—and that the price reflects the high cost of developing new medications, which reportedly exceeds $1 billion.

Yet even doctors involved with developing Gleevac, such as Dr. Brian Druker, are criticizing Novartis, which raked in $4.7 billion in sales for the drug in 2012.

“If you are making $3 billion a year on Gleevec, could you get by with $2 billion?” Dr. Druker, now director of Knight Cancer Institute at Oregon Health and Science University, said in an interview with The New York Times. “When do you cross the line from essential profits to profiteering?”
Author

Posts

Viewing 3 posts - 1 through 3 (of 3 total)

You must be logged in to reply to this topic.